Ophthalmology denials and appeals.
Knowing that a claim came back as CO-50 or PR-204 isn't the same as knowing what to do with it. Some ophthalmology denials are billing-error corrections that never should have gone through an appeal process at all; others are genuine coverage disputes that need the actual five-level Medicare appeals machinery, filed inside real deadlines, against a real dollar threshold. This guide covers the process itself, three denial patterns that sit underneath the specialty's headline CARC codes, and the specific evidence that turns an anti-VEGF reauthorization denial around.
Key takeaways
- CO-16 on an anti-VEGF claim is usually self-inflicted, not a coverage dispute. A missing JW or JZ attestation is a corrected-claim fix, not a five-level appeal.
- Medicare Advantage doesn't run the fee-for-service appeal clock. An MA denial goes through organization determination and the plan's own reconsideration, with an automatic forward to an independent review entity — not straight to a MAC redetermination.
- CY2026 raised the ALJ amount-in-controversy threshold to $200 and judicial review to $1,960. A claim below that line still qualifies if aggregated with similar denied claims.
- An anti-VEGF reauthorization appeal needs treatment-response evidence, not a restated diagnosis. Stable or improved acuity and a documented drop in OCT fluid are what a clinical reviewer actually looks for.
Sort the denial before you draft anything
Our ophthalmology billing and coding guide covers the specialty's five most common denials — CO-50 medical necessity, CO-97 bundling, CO-18 duplicate, PR-204 not covered, and CO-151 frequency — along with the appeal argument for each. This guide goes one level deeper: three more CARC patterns that hide underneath those, the actual mechanics of the Medicare appeals process that a genuine dispute has to move through, and the specific evidence an anti-VEGF reauthorization denial needs to reverse.
The first decision on any denial is whether it's a claim-level defect or a coverage dispute — they need entirely different responses. A defect (a missing modifier, a transposed NDC, an expired filing window) needs a corrected claim or a straightforward resubmission. A coverage dispute needs the actual appeals process: a written argument, cited policy, and supporting documentation, filed inside a real deadline. Treating the first kind like the second burns the appeal clock on something that never needed it.
Three denial patterns underneath the headline codes
| Denial | Why it fires in ophthalmology | Fix |
|---|---|---|
| CO-16 Claim/service lacks information | Most often an anti-VEGF drug line missing the required JW or JZ waste attestation, or an NDC that doesn't match the product actually administered | Correct the claim line and resubmit — this is a billing-error fix, not an appeal, and treating it as one wastes the 120-day redetermination clock |
| CO-197 Precertification/authorization absent | A Medicare Advantage plan required prior authorization for cataract surgery or a specific site of service that traditional Medicare doesn't require it for at all | Confirm the specific MA plan's PA policy before scheduling; appeal only if authorization was actually obtained and documented, not assumed |
| CO-29 Timely filing limit expired | Either the original claim or the appeal itself was submitted after the payer's own filing deadline — two separate clocks practices routinely conflate | Track the claim's timely-filing deadline and the redetermination's 120-day window as two different dates; once either expires, only a documented good-cause exception reopens it |
The five-level Medicare appeals process
A genuine coverage dispute on a traditional Medicare claim moves through five defined levels, each with its own decision-maker, filing deadline, and decision timeframe. Skipping a deadline at any level doesn't just slow things down — it closes that level off, absent a documented good-cause exception.
| Level | Who decides | Filing deadline | Typical decision time |
|---|---|---|---|
| 1. Redetermination | The MAC that processed the claim | 120 days from the remittance advice | ≈60 days |
| 2. Reconsideration | Qualified Independent Contractor (QIC) | 180 days from the redetermination decision | ≈60 days |
| 3. ALJ hearing | Office of Medicare Hearings and Appeals | 60 days from the QIC decision; amount in controversy ≥ $200 (CY2026) | Highly variable, often well beyond 90 days given current OMHA backlogs |
| 4. Council review | Medicare Appeals Council (Departmental Appeals Board) | 60 days from the ALJ decision | Variable |
| 5. Judicial review | Federal district court | 60 days from the Council decision; amount in controversy ≥ $1,960 (CY2026) | Set by the court's docket |
The CY2026 amount-in-controversy figures come from CMS's annual inflation adjustment, published in the Federal Register; a single claim below the threshold can still qualify for an ALJ hearing if it's aggregated with other denied claims that share a common question, which is routinely how a practice with a run of similar anti-VEGF or imaging-frequency denials gets there.
Medicare Advantage runs a different clock entirely. An MA plan issues an organization determination rather than a claim adjudication, and a denial goes first to the plan's own reconsideration; if the plan upholds it, the plan must automatically forward the case to CMS's contracted independent review entity rather than waiting for the practice to escalate. Only after that entity upholds the denial does the case reach the same ALJ, Council, and court levels as fee-for-service. An expedited 72-hour track is available at reconsideration when a standard timeframe could seriously jeopardize the patient's vision — relevant for a time-sensitive anti-VEGF reauthorization more than most other ophthalmology denials.
Anti-VEGF reauthorization denials: what actually reverses them
Anti-VEGF therapy for wet age-related macular degeneration (H35.3211 and its laterality/activity siblings) and diabetic macular edema is a recurring authorization cycle, not a one-time approval. Most reauthorization denials share the same root cause: the request restated the diagnosis instead of showing the treatment worked. The reviewer already has the original approval on file; what a reauthorization needs to demonstrate is response to treatment:
- Visual acuity trendStable or improved best-corrected visual acuity across the treatment interval, documented at each injection visit — not just the most recent value in isolation.
- OCT fluid trendA documented reduction, or sustained absence, of central subfield thickness or intraretinal/subretinal fluid on serial OCT — the imaging evidence a reviewer weighs more heavily than a narrative description.
- Treat-and-extend intervalThe actual dosing interval used, and why it changed or held steady, tied to the clinical findings above rather than stated as a fixed schedule.
- Step-therapy historyWhere a plan required bevacizumab first, the specific date and outcome of that trial — not a generic statement that step therapy was "tried and failed."
A reauthorization request or appeal that skips straight to "continue current therapy, diagnosis unchanged" is the single most common reason a genuinely responding patient still gets a denial that has to be appealed rather than approved the first time.
Before drafting any appeal, sort the denial into one of two buckets: a claim-level defect (CO-16, CO-29 filed after the window) that a corrected claim fixes in days, or a genuine coverage dispute (CO-50, PR-204, an anti-VEGF reauthorization denial) that needs the real five-level process. Staff who draft full appeal letters for CO-16 denials burn the 120-day redetermination clock on something a resubmission would have resolved a week earlier.
Building the appeal letter
An appeal that reverses a denial reads like a policy argument, not a plea:
- IdentifiersPatient name, claim number, date of service, and CARC/RARC code, matched exactly to the remittance advice.
- The specific policyThe governing LCD, NCD, or plan policy cited by document ID and MAC or plan name — never "per CMS."
- The record tied to the policyA sentence connecting the chart to the policy's covered-diagnosis or documentation language, not a general necessity statement.
- Supporting documentationOperative notes, OCT trend data, visual field results, or photographs referenced by date and attached.
- Signature and deadline proofReviewing provider's name and credential, plus a dated confirmation of timely submission — never file within days of the deadline unconfirmed.
Do and don't
- File a redetermination within 120 days, and build the packet well before that deadline, not at it.
- Cite the specific MAC or plan policy by document ID, never "per CMS."
- Separate a genuine coverage dispute from a billing-error correction before deciding which process to use.
- Track a Medicare Advantage plan's own PA and appeal timelines separately from fee-for-service Medicare rules.
- Don't send a full appeal letter for a CO-16 defect a corrected claim would fix.
- Don't restate the diagnosis alone on an anti-VEGF reauthorization — show the treatment response.
- Don't assume a claim below the ALJ threshold is a dead end before checking whether it can be aggregated.
- Don't assume an MA plan denial follows the fee-for-service redetermination-to-QIC path.
Writing off ophthalmology denials instead of appealing them?
We'll sort your recent ophthalmology denials into billing-error fixes versus real coverage disputes, and build the appeal packet for the ones actually worth fighting.
Frequently asked questions
What's the deadline to file a Medicare redetermination?
120 days from the date on the remittance advice that carried the denial. The MAC then has roughly 60 days to decide. Missing the 120-day window doesn't just delay the appeal — it forfeits the level entirely absent a good-cause exception, so track that clock separately from the original claim's timely-filing deadline.
Do Medicare Advantage denials follow the same appeal process as traditional Medicare?
No. Traditional Medicare starts with a redetermination at the MAC; an MA plan instead issues an organization determination, followed by the plan's own reconsideration, and if it upholds the denial it must automatically forward the case to CMS's contracted independent review entity rather than waiting for the provider to escalate. An expedited 72-hour track is available when delay could seriously jeopardize the patient's vision — relevant for time-sensitive anti-VEGF reauthorizations. Confirm the specific MA plan's process rather than assuming it mirrors fee-for-service Medicare.
What's the amount in controversy required to request an ALJ hearing in 2026?
$200 for calendar year 2026, per CMS's annual inflation adjustment published in the Federal Register. Judicial review at the fifth level requires a higher $1,960 for CY2026. Both apply across Medicare Part A, Part B, and Medicare Advantage appeals, and a claim below the ALJ threshold can still be aggregated with similar claims to meet it.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.